Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (61-70 of 208) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Challenges in recognizing treatment-related neuroendocrine prostate cancerHimisha Beltran, Scott T Tagawa, Kyung Park, et al.
Prostate Cancer and Prostatic Diseases|July 15, 2022
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateScott T Tagawa, Krishnan Ramaswamy, Ahong Huang, et al.
Prostate Cancer and Prostatic Diseases|January 18, 2022
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateScott T Tagawa, Krishnan Ramaswamy, Ahong Huang, et al.
Investigational New Drugs|July 26, 2012
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancerGary Hudes, Scott T Tagawa, Young E Whang, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2021
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateScott T Tagawa, Krishnan Ramaswamy, Ahong Huang, et al.
JCO Oncology Practice|January 18, 2022
Use of Biosimilar Medications in OncologyZeina Nahleh, Gary H Lyman, Richard L Schilsky, et al.
Blood|December 23, 2018
Arterial thromboembolic events preceding the diagnosis of cancer in older personsBabak B Navi, Anne S Reiner, Hooman Kamel, et al.
Cancer|July 2, 2003
Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanomaScott T Tagawa, Peter Lee, Jolie Snively, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 17, 2018
Antibody-Drug Conjugates in Bladder CancerPanagiotis J Vlachostergios, Christopher D Jakubowski, Muhammad J Niaz, et al.
Pageof 21

Showing results (61-70 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Challenges in recognizing treatment-related neuroendocrine prostate cancerHimisha Beltran, Scott T Tagawa, Kyung Park, et al.
Prostate Cancer and Prostatic Diseases|July 15, 2022
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateScott T Tagawa, Krishnan Ramaswamy, Ahong Huang, et al.
Prostate Cancer and Prostatic Diseases|January 18, 2022
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateScott T Tagawa, Krishnan Ramaswamy, Ahong Huang, et al.
Investigational New Drugs|July 26, 2012
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancerGary Hudes, Scott T Tagawa, Young E Whang, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2021
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateScott T Tagawa, Krishnan Ramaswamy, Ahong Huang, et al.
JCO Oncology Practice|January 18, 2022
Use of Biosimilar Medications in OncologyZeina Nahleh, Gary H Lyman, Richard L Schilsky, et al.
Blood|December 23, 2018
Arterial thromboembolic events preceding the diagnosis of cancer in older personsBabak B Navi, Anne S Reiner, Hooman Kamel, et al.
Cancer|July 2, 2003
Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanomaScott T Tagawa, Peter Lee, Jolie Snively, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 17, 2018
Antibody-Drug Conjugates in Bladder CancerPanagiotis J Vlachostergios, Christopher D Jakubowski, Muhammad J Niaz, et al.
Pageof 21